3 Blood Cancer Drug Hopefuls in the Spotlight
At the recent ASCO conference, Infinity Pharmaceuticals posted solid efficacy data for its non-Hodgkin's lymphoma drug, but shares cratered, closing down 39%. The problem is that Infinity's drug, while promising, doesn't exist in a vacuum and will see competition from two of health care's biggest players.
In this video, health-care analyst David Williamson takes a closer look at the three promising blood cancer drugs that caused some big stock movements earlier this month.
Is bigger really better?
Involved in everything from baby powder to biotech, Johnson & Johnson has its critics convinced that the company is spread way too thin. If you want to know if J&J is nothing but a bloated corporate whale or a well-diversified giant that's perfect for your portfolio, check out the Fool's new premium report outlining the Johnson & Johnson story in terms that any investor can understand. Claim your copy by clicking here now.
The article 3 Blood Cancer Drug Hopefuls in the Spotlight originally appeared on Fool.com.
David Williamson owns shares of Johnson & Johnson. Follow David on Twitter: @MotleyDavid.The Motley Fool recommends Gilead Sciences and Johnson & Johnson and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.